Biotech, like everything else, has been taking it hard. There are still a few buyers out there though. Let's shuffle through some trials and see who is still a bull.
today: CELG
Revlimid is changing the how multiple myeloma (blood cancer) is being treated.
some background:
Lenalidomide (Revimid) is used to treat a type of blood disorder known as myelodysplastic syndrome. Lenalidomide is also used along with other drugs to treat people with the cancer known as multiple myeloma. CELG also has an impressive pipeline in oncology solid tumors that should see fruition in the next few years.
Revlimid is used in conjunction with an anti-inflammatory drug called dexamethasone in patients.
CELG closed up today in average trading (avg. volume ) up 64 cents to 54.32.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment